{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-196599","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2022-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.908292+00:00","generated_at":"2026-06-24T12:16:09.940521+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA grants Priority Review for Apellis' pegcetacoplan to treat geographic atrophy; PDUFA Nov 26, 2022","bullets":["FDA accepted and granted Priority Review for intravitreal pegcetacoplan NDA for geographic atrophy (GA).","PDUFA target action date set for November 26, 2022; no advisory committee meeting planned.","Apellis plans to submit marketing authorization application to European Medicines Agency in H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-196599","json":"https://secwatch.observer/filing/0001193125-22-196599.json","markdown":"https://secwatch.observer/filing/0001193125-22-196599.md","text":"https://secwatch.observer/filing/0001193125-22-196599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522196599/0001193125-22-196599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522196599/d384280d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T12:16:09.940521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}